Copperwynd Financial LLC Buys 601 Shares of Thermo Fisher Scientific Inc. $TMO

Copperwynd Financial LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,031 shares of the medical research company’s stock after purchasing an additional 601 shares during the period. Copperwynd Financial LLC’s holdings in Thermo Fisher Scientific were worth $1,634,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Tectonic Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 7.7% during the second quarter. Tectonic Advisors LLC now owns 3,443 shares of the medical research company’s stock valued at $1,396,000 after buying an additional 247 shares during the last quarter. Fulton Breakefield Broenniman LLC boosted its holdings in Thermo Fisher Scientific by 31.2% during the second quarter. Fulton Breakefield Broenniman LLC now owns 622 shares of the medical research company’s stock worth $252,000 after purchasing an additional 148 shares during the last quarter. Cohen Investment Advisors LLC boosted its holdings in Thermo Fisher Scientific by 12.4% during the second quarter. Cohen Investment Advisors LLC now owns 6,650 shares of the medical research company’s stock worth $2,696,000 after purchasing an additional 733 shares during the last quarter. Vontobel Holding Ltd. boosted its holdings in Thermo Fisher Scientific by 4.5% during the second quarter. Vontobel Holding Ltd. now owns 1,089,103 shares of the medical research company’s stock worth $441,588,000 after purchasing an additional 46,743 shares during the last quarter. Finally, Maryland State Retirement & Pension System boosted its holdings in Thermo Fisher Scientific by 2.8% during the second quarter. Maryland State Retirement & Pension System now owns 18,355 shares of the medical research company’s stock worth $7,442,000 after purchasing an additional 496 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $536.21 on Thursday. The firm’s 50 day simple moving average is $486.09 and its 200 day simple moving average is $448.21. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $202.48 billion, a PE ratio of 31.01, a price-to-earnings-growth ratio of 2.93 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TMO. Evercore ISI boosted their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a report on Tuesday. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Finally, Barclays boosted their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $590.60.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.